How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator

被引:31
作者
Gandaglia, Giorgio [1 ]
van den Bergh, Roderick C. N. [3 ]
Tilki, Derya [4 ,5 ]
Fossati, Nicola [1 ]
Ost, Piet [8 ]
Surcel, Christian I. [9 ]
Sooriakumaran, Prasanna [10 ]
Tsaur, Igor [6 ]
Valerio, Massimo [11 ]
Kretschmer, Alexander [7 ]
Zaffuto, Emanuele [1 ]
Salomon, Laurent [12 ]
Montorsi, Francesco [1 ,2 ]
Graefen, Markus [4 ]
van der Poel, Henk [3 ]
de la Taille, Alexandre [12 ]
Briganti, Alberto [1 ,2 ]
Ploussard, Guillaume [12 ,13 ]
机构
[1] IRCCS Osped San Raffaele, URI, Unit Urol, Div Oncol, Milan, Italy
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[4] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[5] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[6] Univ Med Mainz, Dept Urol, Mainz, Germany
[7] Ludwig Maximilians Univ Munchen, Urol Klin & Poliklin, Campus Grosshadern, Munich, Germany
[8] Ghent Univ Hosp, Dept Radiotherapy, Ghent, Belgium
[9] Fundeni Clin Inst, Ctr Urol Surg Dialysis & Renal Transplantat, Bucharest, Romania
[10] Univ Coll London Hosp, Dept Urooncol, London, England
[11] CHU Vaudois, Dept Urol, Lausanne, Switzerland
[12] Henri Mondor Hosp, AP HP, Dept Urol, Creteil, France
[13] St Jean Languedoc Hosp, Dept Urol, Toulouse, France
关键词
misclassification; radical prostatectomy; pathological outcomes; #PCSM; #ProstateCancer; TERM OUTCOMES; FOLLOW-UP; MANAGEMENT; IMPROVE; MEN;
D O I
10.1111/bju.14391
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivePatients and MethodsTo develop a novel tool to increase the number of patients with prostate cancer eligible for active surveillance (AS) without increasing the risk of unfavourable pathological features (i.e., misclassification) at radical prostatectomy (RP). Overall, 16049 patients with low- or intermediate-risk prostate cancer treated with RP were identified. Misclassification was defined as non-organ confined or grade group 3 disease at RP. The coefficients of a logistic regression model predicting misclassification were used to develop a risk score. We then performed a systematic analysis of different thresholds to discriminate between patients with or without unfavourable disease and we compared it to available AS criteria. ResultsConclusionsOverall, 5289 (33.0%) patients had unfavourable disease. At multivariable analyses, PSA level, clinical stage, biopsy grade group, the number of positive cores, and PSA density were associated with the risk of unfavourable disease (all P < 0.001). The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were associated with a lower risk of misclassification (13%) compared to other criteria. Overall, 3303 (20.6%) patients were eligible according to the PRIAS protocol. The adoption of an 18% threshold according to the risk score increased the proportion of eligible patients from 20.6% to 29.4% without increasing the risk of misclassification as compared to the PRIAS criteria. The use of a novel risk score for AS selection would result in an absolute increase of 10% in the number of patients eligible for this approach without increasing the risk of misclassification.
引用
收藏
页码:823 / 830
页数:8
相关论文
共 31 条
  • [11] Pathologic Prostate Cancer Characteristics in Patients Eligible for Active Surveillance: A Head-to-Head Comparison of Contemporary Protocols
    Iremashvili, Viacheslav
    Pelaez, Liset
    Manoharan, Murugesan
    Jorda, Merce
    Rosenberg, Daniel L.
    Soloway, Mark S.
    [J]. EUROPEAN UROLOGY, 2012, 62 (03) : 462 - 468
  • [12] Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors
    Kattan, MW
    Eastham, JA
    Wheeler, TM
    Maru, N
    Scardino, PT
    Erbersdobler, A
    Graefen, M
    Huland, H
    Koh, H
    Shariat, SF
    Slawin, KM
    Ohori, M
    [J]. JOURNAL OF UROLOGY, 2003, 170 (05) : 1792 - 1797
  • [13] Active surveillance for prostate cancer compared with immediate treatment An Economic Analysis
    Keegan, Kirk A.
    Dall'Era, Marc A.
    Durbin-Johnson, Blythe
    Evans, Christopher P.
    [J]. CANCER, 2012, 118 (14) : 3512 - 3518
  • [14] Active surveillance for low-risk prostate cancer
    Klotz, Laurence
    [J]. CURRENT OPINION IN UROLOGY, 2017, 27 (03) : 225 - 230
  • [15] Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
    Klotz, Laurence
    Vesprini, Danny
    Sethukavalan, Perakaa
    Jethava, Vibhuti
    Zhang, Liying
    Jain, Suneil
    Yamamoto, Toshihiro
    Mamedov, Alexandre
    Loblaw, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) : 272 - U75
  • [16] The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance
    Ma, Ting Martin
    Tosoian, Jeffrey J.
    Schaeffer, Edward M.
    Landis, Patricia
    Wolf, Sacha
    Macura, Katarzyna J.
    Epstein, Jonathan I.
    Mamawala, Mufaddal
    Carter, H. Ballentine
    [J]. EUROPEAN UROLOGY, 2017, 71 (02) : 174 - 180
  • [17] Development and Multi-Institutional Validation of an Upgrading Risk Tool for Gleason 6 Prostate Cancer
    Matthew Truong
    Slezak, Jon A.
    Lin, Chee Paul
    Iremashvili, Viacheslav
    Sado, Martins
    Razmaria, Aria A.
    Leverson, Glen
    Soloway, Mark S.
    Eggener, Scott E.
    Abel, E. Jason
    Downs, Tracy M.
    Jarrard, David F.
    [J]. CANCER, 2013, 119 (22) : 3992 - 4002
  • [18] Adverse Disease Features in Gleason Score 3+4 "Favorable Intermediate-Risk'' Prostate Cancer: Implications for Active Surveillance
    Morlacco, Alessandro
    Cheville, John C.
    Rangel, Laureano J.
    Gearman, Derek J.
    Karnes, R. Jeffrey
    [J]. EUROPEAN UROLOGY, 2017, 72 (03) : 442 - 447
  • [19] Low-risk Prostate Cancer: Identification, Management, and Outcomes
    Moschini, Marco
    Carroll, Peter R.
    Eggener, Scott E.
    Epstein, Jonathan I.
    Graefen, Markus
    Montironi, Rodolfo
    Parker, Christopher
    [J]. EUROPEAN UROLOGY, 2017, 72 (02) : 238 - 249
  • [20] EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
    Mottet, Nicolas
    Bellmunt, Joaquim
    Bolla, Michel
    Briers, Erik
    Cumberbatch, Marcus G.
    De Santis, Maria
    Fossati, Nicola
    Gross, Tobias
    Henry, Ann M.
    Joniau, Steven
    Lam, Thomas B.
    Mason, Malcolm D.
    Matveev, Vsevolod B.
    Moldovan, Paul C.
    van den Bergh, Roderick C. N.
    Van den Broeck, Thomas
    van der Poel, Henk G.
    van der Kwast, Theo H.
    Rouviere, Olivier
    Schoots, Ivo G.
    Wiegel, Thomas
    Cornford, Philip
    [J]. EUROPEAN UROLOGY, 2017, 71 (04) : 618 - 629